HHS Public Access Author manuscript Author Manuscript

AFCS Nat Mol Pages. Author manuscript; available in PMC 2017 August 03. Published in final edited form as: AFCS Nat Mol Pages. 2011 ; 2011: .

Cathepsin B: Basis Sequence: Mouse Dora Cavallo-Medved1, Kamiar Moin2, and Bonnie Sloane2 1Biological

Sciences, University of Windsor, ON N9B 3P4, CA

2Pharmacology,

Wayne State University, MI 48201, US

Author Manuscript

Protein Function

Author Manuscript Author Manuscript

Cathepsin B is a member of the papain-like family of cysteine proteases and is synthesized as a preproenzyme of 339 amino acids with a calculated molecular weight of approximately 38 kDa [reviewed in (Kirschke et al. 1995; Mort and Buttle 1997)]. Cathepsin B is a bilobal protein with its catalytic site located at the interface between the two lobes (Musil et al. 1991). The amino acids cysteine, histidine and aspartic acid comprise the catalytic triad of the enzyme, with cysteine on the left lobe interacting with histidine on the right lobe to catalyze peptide bond cleavage. Cathepsin B, in contrast to other cysteine cathepsins of the papain-like family, exhibits both endopeptidase and exopeptidase activity. As an endopeptidase, cathepsin B favors amino acids with a large hydrophobic side chain in the P2 site of the protein/peptide substrate (i.e., two residues N terminus of the scissile bond), although it will also accept arginine at this site (Hasnain et al. 1993; Gosalia et al. 2005; Choe et al. 2006). As an exopeptidase, cathepsin B can remove two amino acids (dipeptide) from the C terminus of a polypeptide substrate, thus classifying the enzyme as a peptidyldipeptidase (Cezari et al. 2002; Cotrin et al. 2004). Unlike other cysteine cathepsins, cathepsin B also contains an occluding loop, which consists of 18 amino acids between Pro107 and Asp124. Two salt bridges between the occluding loop and the mature enzyme (at positions His110–Asp22 and Arg116–Asp224) partially block the substrate-binding cleft, thereby promoting its peptidyldipeptidase activity (Musil et al. 1991; Illy et al. 1997). Displacement of the occluding loop is pH dependent and results in the modulation of cathepsin B activity, with exopeptidase and endopeptidase activities being favored at acidic and neutral/alkaline pH values, respectively. Endopeptidase activity at neutral/alkaline pH values is due to disruption of the salt bridges between the occluding loop and the mature enzyme and unfolding of the enzyme (Nägler et al. 1997). In procathepsin B, the occluding loop cannot interact with the active site cleft of the enzyme due to the propeptide that passes directly across the active site cleft (Turk et al. 1996).

In vivo studies also indicate that cathepsin B functions as both an endopeptidase and an exopeptidase. Genetic ablation of cathepsin B is not lethal, nor is genetic ablation of the cysteine protease cathepsin L, which is solely an endopeptidase; however, genetic ablation of both cathepsins B and L is lethal (Sevenich et al. 2006). On the other hand, in a transgenic

Correspondence should be addressed to Bonnie Sloane: [email protected].

Cavallo-Medved et al.

Page 2

Author Manuscript

mouse model for mammary cancer, genetic ablation of cathepsin B and therefore its absence from the mammary cancer cell membrane is compensated for by a redistribution of the cysteine protease cathepsin X, which is solely a carboxypeptidase, to the membrane of these cells (Vasiljeva et al. 2006).

Author Manuscript

Under normal physiological conditions, active cathepsin B is localized to the endosomal/ lysosomal compartment and is primarily involved in routine turnover of both intracellular and extracellular proteins, thus maintaining homeostatic metabolic activity within cells. Other cellular functions for cathepsin B include the regulation of pro-hormone and proenzyme activation, antigen processing, inflammatory responses against antigens, tissue remodeling and apoptosis [reviewed in (Mort and Buttle 1997; Reiser et al. 2010)]. For example, in the thyroid, proteolytic processing of the prohormone thyroglobulin (Tg) by secreted cathepsin B (i.e., nonlysosomal) generates the thyroid hormones thyroxine (T4) and triiodothyronine (T3) (Brix et al. 1996; Linke et al. 2002).

Author Manuscript

Expression and activity of cathepsin B have been correlated with a number of pathologies, including cancer, arthritis, pancreatitis, cardiovascular disease and Alzheimer’s disease. In cancer, overexpression of cathepsin B has been reported in breast, prostate, brain, esophageal, gastric, lung, ovarian, thyroid, skin and colon cancers [reviewed in (Roshy et al. 2003; Jedeszko and Sloane 2004; Mohamed and Sloane 2006)]. Upregulation of cathepsin B expression is predictive of poor prognosis in several tumors, e.g., colon carcinoma (Campo et al. 1994) and ovarian carcinoma (Scorilas et al. 2002). Moreover, a positive correlation between cathepsin B expression and metastasis of carcinoma cells to lymph nodes has been shown in breast (Foekens et al. 1998), prostate (Sinha et al. 2002) and gastric (Czyzewska et al. 2008) cancers. Overexpression of cathepsin B is often accompanied by an altered trafficking of the enzyme to the plasma membrane and secretion into the extracellular milieu [reviewed in (Cavallo-Medved and Sloane 2003; Roshy et al. 2003; Mohamed and Sloane 2006)]. Cathepsin B retains activity at the neutral pH found in the extracellular milieu, particularly in the presence of large extracellular matrix (ECM) proteins (Buck et al. 1992). Cathepsin B directly degrades and remodels the ECM, thereby promoting migration and invasion of tumor cells. In addition, cathepsin B participates in proteolytic networks as an activator of downstream serine proteases and metalloproteases that also contribute to tumorigenesis and invasion. Possible mechanisms for the overexpression of cathepsin B in cancer cells are discussed below in the section ‘Regulation of Concentration’.

Author Manuscript

Upregulation of cathepsin B has been shown in the synovium of rheumatoid arthritis patients, and in particular in synovial cells at the site of joint destruction (Hansen et al. 2000). In the synovial fluid, cathepsin B participates in collagen degradation, which is inhibited by CA074, a highly selective inhibitor of cathepsin B, consistent with a role for cathepsin B in the progression of the disease (Hashimoto et al. 2001). In osteoarthritis, cathepsin B and its RNA variant CB(−2) (i.e., a cathepsin variant lacking exon 2) are overexpressed in osteoarthritic cartilage and osteophytes as compared with normal cartilage, an effect correlated with an increase in secretion of procathepsin B and its proteolytic activation (Berardi et al. 2001).

AFCS Nat Mol Pages. Author manuscript; available in PMC 2017 August 03.

Cavallo-Medved et al.

Page 3

Author Manuscript

Cathepsin B has a role in acute pancreatitis. In this disease, cathepsin B prematurely activates latent precursor digestive enzymes such as trypsinogen within zymogen granules of pancreatic acinar cells, thus leading to destruction of the gland [reviewed in (Lerch and Halangk 2006; van Acker et al. 2006)]. In vitro assays have demonstrated that cathepsin B can activate one of the resident zymogens, trypsinogen, into its active form, trypsin. Moreover, in vivo studies using cathepsin B-deficient mice revealed that 90% of the intrapancreatic trypsinogen activation during pancreatitis is dependent upon cathepsin B activity (Halangk et al. 2000; Van Acker et al. 2002; van Acker et al. 2006).

Author Manuscript

In atherosclerosis, cathepsin B has roles in lipid metabolism [reviewed in (Lutgens et al. 2007)]. Uptake of modified (i.e., oxidized) low-density lipoprotein (LDL) particles results in localization of cathepsin B within the cytoplasm, most likely via the disruption of lysosomal membranes, and results in the activation of caspases and subsequent apoptosis (Li et al. 2001; Li and Yuan 2004). In atherosclerotic lesions of apolipoprotein E (apoE)-deficient mice, cathepsin B mRNA and protein levels are increased in areas adjacent to the lumen and within macrophages (Chen et al. 2002). In vivo imaging of cathepsin B localized the enzyme in atherosclerotic plaques (Chen et al. 2002), thus suggesting that the enzyme might be a useful diagnostic tool for atherosclerosis. Indeed, anti-atherosclerotic therapies using atorvastatin and glucosamine reduce the cathepsin B-related imaging signal in apoEdeficient mice (Kim et al. 2009). In contrast, a protective role for cathepsin B in atherosclerosis has also been suggested. In smooth muscle cells, inhibition of cathepsin B activity reduces lysosomal degradation of modified LDL and this accumulation of LDL induces foam cell formation (Tertov and Orekhov 1997).

Author Manuscript

Cathepsin B has also been localized to secretory vesicles of neuronal cells, and its activity within these vesicles produces β-amyloid (Aβ) peptides by cleavage of amyloid precursor protein (APP) at the wild-type (wt) β-secretase site (Hook et al. 2005; Hook et al. 2008). In transgenic mice expressing human APP containing the wt β-secretase site, which is present in most Alzheimer’s disease patients, inhibition of cathepsin B activity results in a reduction of Aβ peptide accumulation, amyloid plaque load, and an improvement in memory deficit (Hook et al. 2008). In cathepsin B knockout mice, there is a decrease in Aβ production and C-terminal β-secretase fragmentation, supporting cathepsin B as a potential therapeutic target for inhibitors to reduce brain Aβ generated from wt APP associated with Alzheimer’s disease (Hook et al. 2009).

Regulation of Activity Author Manuscript

Cathepsin B is an important participant within cellular proteolytic networks as determined mainly from in vitro data. One of the activating proteases for cathepsin B is cathepsin D, an aspartic cathepsin (van der Stappen et al. 1996). Cathepsin B is also activated by a number of other proteases, including the serine proteases cathepsin G, urokinase-type plasminogen activator (uPA), tissue-type plasminogen activator (tPA) and elastase (Dalet-Fumeron et al. 1993; Dalet-Fumeron et al. 1996). Additionally, the interaction between cathepsin B and uPA is reciprocal, as cathepsin B can also activate pro-uPA (Kobayashi et al. 1991). Crystal structure data has contributed significantly to understanding the mechanism of procathepsin B activation (Turk et al. 1996; Podobnik et al. 1997; Pungercar et al. 2009). Cathepsin B can

AFCS Nat Mol Pages. Author manuscript; available in PMC 2017 August 03.

Cavallo-Medved et al.

Page 4

Author Manuscript

undergo autocatalytic activation within the acidic environment of the late endosome and lysosomes. This is a bimolecular process that results in proteolytic removal of the propeptide with subsequent activation of the enzyme (Podobnik et al. 1997; Rozman et al. 1999) being triggered by proenzyme activity (Pungercar et al. 2009). Autoactivation of cathepsin B can be accelerated by binding of the enzyme to polyanionic polysaccharides such as dextran sulfate and naturally occurring glycosaminoglycans, including heparin, heparin sulfate and chondroitin sulfate (Caglic et al. 2007).

Author Manuscript

Activity of cathepsin B is also modulated by the position of its occluding loop. The occluding loop has 2 histidine residues that at acidic pH interact with the substrate binding cleft and exhibit carboxypeptidase activity (i.e., exopeptidase) of the enzyme. At acidic pH, cathepsin B has been shown to degrade types II, IX and XI collagen (Maciewicz et al. 1990). Displacement of the occluding loop away from the active site cleft, as observed under neutral/alkaline conditions, allows protein substrates access to the active site and the enzyme to function as an endopeptidase (Musil et al. 1991; Illy et al. 1997). Interaction of the occluding loop of cathepsin B with heparin sulfate at the cell surface structurally stabilizes the enzyme under alkaline conditions and potentiates endopeptidase activity (Almeida et al. 2001). This interaction is significant in possibly associating cathepsin B to the plasma membrane and regulating its enzymatic activity.

Author Manuscript Author Manuscript

The final level of regulation of cathepsin B activity is by endogenous inhibitors such as cystatins (Barrett et al. 1986; Turk and Bode 1991; Turk et al. 1997). Cystatins are inhibitors of papain-like cysteine proteases and are subdivided into three families (i.e., cystatin I, II and III) based on their distinct structural details, distribution in the body and physiological roles [reviewed in (Abrahamson et al. 2003)]. The actions of these inhibitors require that the occluding loop of cathepsin B be displaced, allowing the inhibitor to bind to the active site cleft. Binding of cystatin C, an extracellular inhibitor belonging to the cystatin II family, to cathepsin B occurs in two steps: 1) an initial weak binding of the inhibitor to the enzyme, followed by 2) a conformational change in the enzyme that is required to displace the occluding loop and allow for a tighter inhibitor-enzyme bond (Musil et al. 1991; Nycander et al. 1998). Inhibition of cathepsin B by cystatin A/stefin A, a cytosolic cystatin I family inhibitor, has also been reported to occur via a similar two-step mechanism (Pavlova et al. 2000). Due to the occluding loop, inhibition of cathepsin B by protein inhibitors is several orders of magnitude weaker than their inhibition of other endopeptidases such as cathepsins L, V and S. A structural analysis of cystatin A/stefin A binding to cathepsin B suggests that the relocation of the occluding loop is an energy-efficient event (Renko et al. 2010). Other inhibitors of cathepsin B activity include cystatin B/stefin B, also a member of the cystatin I family (Turk et al. 1997); thyropins including equistatin from sea anemone (Lenarcic et al. 1997), saxiphilin from bullfrog (Lenarcic et al. 2000) and chum salmon egg cysteine proteinase inhibitor (Yamashita and Konagaya 1996); and clitocypin from fungi (Brzin et al. 2000). Spi2A, a member of the anti-chymotrypsin family of serine protease inhibitors (serpins), has also been shown to inhibit cathepsin B activity and protect cells from caspasedependent apoptosis (Liu et al. 2003). Unlike other inhibitors of the anti-chymotrypsin family, Spi2A is not secreted and resides in the cytoplasm.

AFCS Nat Mol Pages. Author manuscript; available in PMC 2017 August 03.

Cavallo-Medved et al.

Page 5

Author Manuscript

Interactions with Ligands and Other Proteins As a constitutively expressed lysosomal protease involved in normal protein turnover, cathepsin B interacts with and hydrolyzes a number of protein substrates. Redistribution of cathepsin B to the cell surface and extracellular milieu allows the enzyme access to ECM protein substrates such as laminin, fibronectin and collagen (Maciewicz et al. 1990; Buck et al. 1992). Although in vitro data has revealed many potential substrates for cathepsin B, with the exception of E-cadherin, little is known about in vivo substrates for this enzyme (Gocheva et al. 2006).

Author Manuscript Author Manuscript

Using a yeast-two hybrid system, several proteins including S100A10, i.e., the light chain of the annexin II heterotetramer (AIIt) (Mai et al. 2000), DP1 and MAGE-3 (Mai and Sloane, unpublished data) have been identified as cathepsin B binding partners. Further in vitro and in vivo analyses (i.e., glutathione S-transferase (GST)-pull down and coimmunoprecipitation assays) revealed that S100A10 binds procathepsin B, but not the mature form of the enzyme (Mai et al. 2000). More specifically, these proteins were shown to co-localize on the surface of both tumor cells (Mai et al. 2000) and endothelial cells (Cavallo-Medved et al. 2009) and within their caveolin-enriched membrane microdomains (Cavallo-Medved et al. 2003; Cavallo-Medved et al. 2005; Cavallo-Medved et al. 2009). AIIt at the cell surface has also been shown to bind heparin (Kassam et al. 1997), which along with heparin sulfate binds cathepsin B at the cell surface (Almeida et al. 2001). The binding of cathepsin B to either heparin or heparin sulfate occurs at the His111 residue of the occluding loop and results in the stabilization of the enzyme at alkaline pH (Almeida et al. 2001). AIIt also binds the serine proteases plasminogen (Kassam et al. 1998) and tPA (Hajjar et al. 1994), which is an activator of cathepsin B. As previously noted, cathepsin B activates pro-uPA (Kobayashi et al. 1991), which in turn is hypothesized to initiate proteolytic events involving the activation of plasminogen, tPA and matrix metalloproteinases (MMPs) at the cell surface [reviewed in (Cavallo-Medved and Sloane 2003). Other binding partners for cathepsin B at the cell surface are α2-macroglobulin and its receptor, which also binds both pro-PA and its inhibitor PAI-1 (Arkona and Wiederanders 1996).

Author Manuscript

Cathepsin B has been reported to play an important role in apoptosis and has been shown to cleave the proapoptotic Bid and degrade a number of anti-apoptotic proteins: Bcl-2, Bcl-xL, Mcl-1, Bak and BimEL (Cirman et al. 2004; Droga-Mazovec et al. 2008). Using a yeast-two hybrid method, the human homologue of SETA binding protein 1 (hSB1) (Liu et al. 2006b), bikunin and TSRC1 (Liu et al. 2006a) have been identified as potential cathepsin B binding proteins. hSB1 binds the multifunctional adaptor protein SETA; bikunin is a member of the Kunitz-type protease inhibitor family and inhibits trypsin, plasmin and leukocyte elastase, whereas the function of TSRC1 remains unknown. Interactions between these proteins and cathepsin B were confirmed using in vitro GST pull-down assays and in vivo coimmunoprecipitation experiments (Liu et al. 2006a; Liu et al. 2006b). Bikunin, hSB1 and TSRC1 also co-localize with cathepsin B in cellular lysosomes; however, their roles in regulating cathepsin B activity remain unknown. Overexpression of hSB1 and bikunin has been shown to suppress tumor necrosis factor (TNF)-triggered apoptosis in OV-90 ovarian

AFCS Nat Mol Pages. Author manuscript; available in PMC 2017 August 03.

Cavallo-Medved et al.

Page 6

Author Manuscript

cancer cells, although only bikunin expression reduced cathepsin B activity in these cells (Liu et al. 2006a; Liu et al. 2006b).

Regulation of Concentration Cathepsin B expression can be regulated at multiple levels. The cathepsin B gene locus is on chromosome 8 (8p22) (Fong et al. 1992), the site of an amplicon that contributes to the malignant progression of esophageal carcinoma. Overexpression of cathepsin B associated with this amplicon is hypothesized to contribute to tumor progression (Hughes et al. 1998). Amplification of the cathepsin B gene has also been found in transformed rat ovarian cells (Abdollahi et al. 1999).

Author Manuscript Author Manuscript

The cathepsin B gene consists of 12 exons (Gong et al. 1993). In human gastric adenocarcinoma cells, there are an additional two small exons, 2a and 2b (Berquin et al. 1995). There have been at least three promoter regions identified as sites for the initiation of transcription [reviewed in (Yan and Sloane 2003)]. The major promoter is located just upstream of exon 1 with other promoter regions upstream of exons 3 and 4. This promoter is TATA-less and GC-rich with a single transcription start site, initially classifying cathepsin B as a housekeeping gene (Berquin et al. 1995). This promoter also contains six Sp1, four Ets, and one USF (E-box) binding sites all located 200 bp upstream of the transcription start site (Yan et al. 2000). Transcriptional activation of the cathepsin B promoter by several transcription factors such as USF1, USF2, Sp1, Sp3, and Ets1 has been shown to have an important role in the regulation of cathepsin B expression (Yan et al. 2000; Yan and Sloane 2003). Sp1 binding to GC-rich regions of the cathepsin B promoter upregulates cathepsin B expression (Yan et al. 2000). In murine melanoma cells, this increase in cathepsin B expression results in increased cell invasion (Szpaderska et al. 2004). Binding of USF1 and USF2 to the E-box is required for cathepsin B promoter activity in both normal and tumor cells (Jane et al. 2002a; Jane et al. 2002b; Yan et al. 2003). On the other hand, a splice variant of USF2, USF2c, binds to the E-box element within the cathepsin B promoter and represses cathepsin B expression (Yan and Sloane 2004). Regulation of cathepsin B expression by Est1 is intriguing as this transcription factor is also upregulated in tumors and is associated with inflammatory and endothelial cells (Yan et al. 2000). Furthermore, Est1 induces expression of other proteases linked to malignant progression (Wasylyk and Wasylyk 1992)

Author Manuscript

Posttranscriptional regulation of cathepsin B gene expression has also been shown. For example, treatment of cells with phorbol ester increases cathepsin B expression by increasing the stability of the mRNA transcript (Berquin et al. 1999). Alternative splicing of the pre-mRNA of cathepsin B is another regulatory mechanism that mediates expression of the enzyme (Gong et al. 1993; Tam et al. 1994; Berquin et al. 1995). Indeed, biosynthesis of cathepsin B from mRNA transcripts missing exons 2 and 3 is more efficient in comparison to its full length counterpart (Zwicky et al. 2003). Two major mRNA species produced from the cathepsin B gene are 2.3 kb and 4.0 kb transcripts, the latter with an extended 3′ untranslated region (UTR). Alternative splicing in the 5′-UTR results in six splice variants and splicing in the 5′-translated regions results in 2 cathepsin B transcripts, one lacking exon 2 [CB(−2)] and another lacking both exons 2 and 3 [CB(−2,3)] (Gong et al. 1993; Tam

AFCS Nat Mol Pages. Author manuscript; available in PMC 2017 August 03.

Cavallo-Medved et al.

Page 7

Author Manuscript

et al. 1994). Since the start codon is located in exon 3, the translated product of CB(−2,3) lacks both the signal peptide and the propeptide and therefore is not transported to intracellular vesicular compartments (Gong et al. 1993). Instead the variant remains cytosolic (Mehtani et al. 1998). Preferential expression of the CB(−2,3) splice variant has also been observed in osteoarthritic cartilage from joints with active disease (Berardi et al. 2001; Baici et al. 2006). Although catalytically inactive (Müntener et al. 2005), the truncated forms of cathepsin B have also been shown to be targeted to mitochondria where they induce cell death and to the cytoplasm where they induce nuclear fragmentation in human chondrocytes and HeLa cells (Müntener et al. 2003; Müntener et al. 2004). Functions of these cathepsin B splice variants are discussed below in the section ‘Splice Variants’.

Author Manuscript

Regulation of cathepsin B at the posttranslational level has also been reported. Transfection of colon epithelial cells with the K-ras4Bval12 oncogene increases cathepsin B expression levels without altering mRNA levels (Yan et al. 1997). Similar results are observed in breast epithelial cells transfected with the c-Ha-ras oncogene (Rozhin et al. 1994). Other posttranslational mechanisms for regulation of cathepsin B expression include altered trafficking of cathepsin B to non-lysosomal compartments as discussed below in the section ‘Subcellular Localization’.

Subcellular Localization

Author Manuscript

Co-translational translocation of cathepsin B into the rough endoplasmic reticulum (rER) results in the formation of a preproenzyme containing 339 amino acids with the subsequent removal of the signal peptide (17 amino acids). Procathepsin B (43/46 kDa) is Nglycosylated at 2 potential sites (one in the propeptide region and another in the heavy chain of the enzyme). Procathepsin B is shuttled to the Golgi apparatus where further modification of the oligosaccharides to unique high-mannose carbohydrates occurs (Takahashi et al. 1984). Phosphorylation of the mannose residues directs the enzyme to the endosomal/ lysosomal compartment via the mannose-6-phosphate receptor pathway. In the endosomal compartment, the enzyme is dissociated from the receptor and the 62-amino acid propeptide is removed from the N terminus, along with 6 amino acids from the C terminus, generating the mature single chain form of cathepsin B (31 kDa). Further processing may occur in the lysosomes, where 2 amino acids between residues 47 and 50 are removed generating a mature double chain form consisting of a heavy chain (25/26 kDa) and a light chain (5 kDa) that are linked via a disulfide bridge [reviewed in (Mort and Buttle 1997)].

Author Manuscript

Redistribution of cathepsin B to the cell surface has been observed in both normal cells such as cytotoxic T lymphocytes (Balaji et al. 2002) and endothelial cells (Cavallo-Medved et al. 2009) as well as in a number of different types of cancer cells [reviewed in (Cavallo-Medved and Sloane 2003; Roshy et al. 2003)]. Cathepsin B has also been localized to focal adhesions in tumor cells (Rempel et al. 1994; Sameni et al. 1995) and podosomes in transformed fibroblasts (Tu et al. 2008). Moreover, the metastatic potential of three melanoma cell lines is positively correlated with an increase in cathepsin B activity in plasma membrane fractions (Sloane et al. 1986). Subcellular fractionation of metastatic murine melanoma cells revealed the presence of the 31 kDa single chain form of cathepsin B on the plasma membrane as three isozymes with pI values of 5.33, 5.2 and 5.1 (Sloane et al. 1986; Moin et

AFCS Nat Mol Pages. Author manuscript; available in PMC 2017 August 03.

Cavallo-Medved et al.

Page 8

Author Manuscript

al. 1998). Activity of cell surface cathepsin B has been demonstrated using both real-time enzymatic assays and live-cell proteolysis assays with confocal imaging (Linebaugh et al. 1999; Sameni et al. 2000). Trafficking of cathepsin B to the cell surface can be mediated by several factors including the expression of oncogenic Ha-ras (Sloane et al. 1994) and Ki-ras (Cavallo-Medved et al. 2003). Specific localization of cathepsin B to caveolae on the cell surface was identified in colorectal and breast carcinoma cells as well as endothelial cells (Cavallo-Medved et al. 2003; Cavallo-Medved et al. 2005; Cavallo-Medved et al. 2009). In these cells, cathepsin B is associated with AIIt within these membrane microdomains along with other proteases including uPA and MMP-2 (Cavallo-Medved et al. 2005; CavalloMedved et al. 2009). Moreover, a decrease in expression of caveolin-1, the main structural protein of caveolae, leads to a decrease in cathepsin B distribution to caveolae and a decrease in pericellular ECM degradation and invasion (Cavallo-Medved et al. 2005).

Author Manuscript

Cathepsin B secretion by normal and cancer cells has been shown to occur via both constitutive and inducible pathways (Kuliawat and Arvan 1994; Linebaugh et al. 1999). Secretion of cathepsin B has been suggested to be due to exocytosis of lysosomes, supported by the evidence that treatment of cells with pH 6.5 alters the distribution of vesicles containing cathepsin B to the cell surface resulting in increased secretion of the enzyme (Rozhin et al. 1994). Membrane vesicles shed from B16 melanoma cells, likely to be what are now known as exosomes, contain cathepsin B (Cavanaugh et al. 1983). Other factors including phorbol ester (Guo et al. 2002), 12-(S)-hydroxyeicosatetraenoic acid (12-S-HETE) (Honn et al. 1994) and interferon-γ (Lemaire et al. 1997) also increase cathepsin B secretion.

Author Manuscript Author Manuscript

Cathepsin B has also been localized in the cytoplasm where it acts as a proapoptotic mediator (Guicciardi et al. 2000). The presence of cathepsin B in the cytoplasm is a transient event as a result of damaged lysosomes. Cathepsin B plays a role in TRAIL-mediated apoptosis (Guicciardi et al. 2007) as well as apoptosis mediated by lysosomotropic reagents (Cirman et al. 2004; Droga-Mazovec et al. 2008). In addition, in hepatocytes exposed to TNF, caspase-8 activation is associated with the release of cathepsin B from acidic vesicles into the cytoplasm, which results in the subsequent release of cytochrome c from mitochondria and activation of caspases 9 and 3 (Guicciardi et al. 2000). Moreover, hepatocytes isolated from cathepsin B knockout mice are resistant to TNF-induced apoptosis (Guicciardi et al. 2000). Further studies also identified cathepsin B as a major contributor to an apoptotic cascade upstream of mitochondria in TNF-mediated hepatocyte apoptosis and the progression of the TNF-induced liver damage (Guicciardi et al. 2001). In contrast, others have found that ablation of cathepsin B in primary tumors of MMTV-PymT (mouse mammary tumor virus- polyoma virus middle T oncogene) mice has no effect on TNFmediated apoptosis (Vasiljeva et al. 2008). In another study, genetic ablation of cathepsin B appeared to increase tumor-associated apoptosis, thus indicating that cathepsin B is not always a pro-apoptotic mediator (Gocheva et al. 2006; Bojic et al. 2007). Nuclear distribution of cathepsin B has been observed for an artificially truncated form of the enzyme (Bestvater et al. 2005). Localization of truncated cathepsin B to the nucleus is mediated by a signal within the heavy chain domain of the enzyme and results in cell death. More recently, immunofluorescence and biochemical data also demonstrated nuclear

AFCS Nat Mol Pages. Author manuscript; available in PMC 2017 August 03.

Cavallo-Medved et al.

Page 9

Author Manuscript

localization of a proteolytically active variant smaller than procathepsin B in thyroid carcinoma cells (Tedelind et al. 2010).

Major Sites of Expression

Author Manuscript

Analysis of the promoter region of cathepsin B indicates that the enzyme is encoded by a housekeeping gene and thus is constitutively expressed in all tissues. Nonetheless, upregulation of cathepsin B mRNA and protein has been observed in cancer cells including prostate, colon, breast, esophageal, gastric, lung, ovarian and thyroid cancer and gliomas and melanomas [reviewed in (Cavallo-Medved and Sloane 2003; Roshy et al. 2003; Jedeszko and Sloane 2004)]. In particular, cathepsin B has been shown to localize to the leading invasive edges of tumors. Cathepsin B staining revealed that the enzyme is distributed to the basal pole of cancer cells. In colon cancer, this redistribution is observed in late adenomas (Yan et al. 1997), a stage subsequent to the activation of Ki-ras. Expression of cathepsin B in stromal cells (i.e., fibroblasts, endothelial cells, macrophages) within the tumor microenvironment has also been reported. In colon cancer, cathepsin B overexpression is observed in both inflammatory macrophages and tumor-associated fibroblasts (Campo et al. 1994). Macrophages associated with breast and prostate tumors also express high levels of cathepsin B (Castiglioni et al. 1994; Fernández et al. 2001). Tumors from transgenic mice expressing human cathepsin B that were crossed with transgenic polyoma virus middle T oncogene breast cancer mice [mouse mammary tumor virus-PymT (MMTV-PymT)] showed increased numbers of tumor-associated B cells, mast cells and CD31+ endothelial cells, which correlate with higher levels of vascular endothelial growth factor (VEGF) in the tumor and serum (Vasiljeva et al. 2006; Sevenich et al. 2011). These data suggest that cathepsin B facilitates increased immune cell infiltration and tumor angiogenesis.

Author Manuscript

Phenotypes

Author Manuscript

Cathepsin B knockout mice are both viable and fertile and do not demonstrate any phenotypes that distinguish them from their wild-type (wt) counterparts (Deussing et al. 1998). This study did show that cathepsin B is not a critical factor in major histocompatibility complex II-mediated antigen presentation, as had been proposed (Deussing et al. 1998). However, in cathepsin B knockout mice under challenging conditions, such as experimental pancreatitis, the premature and intracellular activation of trypsinogen that is followed by acinar cell necrosis is largely reduced in the absence of cathepsin B (Halangk et al. 2000). Deletion of the cathepsin B gene in mice reduces TNFassociated hepatocyte apoptosis, by inhibiting mitochondrial release of cytochrome c and caspase 9 and 3 activation and TNF- liver damage and animal mortality (Guicciardi et al. 2001). Excessive accumulation of saturated free fatty acids in liver cells directly induces mitochondrial dysfunction and oxidative stress. This stress was shown to be dependent upon lysosomal disruption and activation of cathepsin B in cathepsin B knockout mice (Li et al. 2008). In transgenic mice expressing human wt-APP, the knockout of cathepsin B significantly reduces the generation of brain Aβ and the APP-derived C-terminal β-secretase fragment, thus supporting the hypothesis that cathepsin B participates in Aβ production from APP containing the wt-β-secretase site (Hook et al. 2008). In a Rip-Tag-2 model, deletion of cathepsin B gene reduces the frequency of initial angiogenic switching in dysplastic

AFCS Nat Mol Pages. Author manuscript; available in PMC 2017 August 03.

Cavallo-Medved et al.

Page 10

Author Manuscript

progenitors, and impairs subsequent development of the tumor vasculature, leading to reduced tumor growth (Joyce et al. 2004). Moreover, null mutations in any one of the three cathepsins B, L, or S disrupts the progression of tumors to invasive carcinoma, indicating that each enzyme has an important, non-redundant role in the process of tumor invasion (Gocheva et al. 2006). On the contrary, mice deficient in both cathepsins B and L die shortly after birth, with neuronal loss and severe brain atrophy (Felbor et al. 2002), an effect not observed in mice deficient in only cathepsin B or cathepsin L. Clearly these data indicate redundancy between the two enzymes in the maintenance of the central nervous system.

Author Manuscript

In mammary tumors of transgenic mice expressing human cathepsin B that have been crossed with transgenic MMTV-PymT mice, there is a 20-fold increase in cathepsin B activity (Sevenich et al. 2011). Although cathepsin B overexpression does not affect tumor onset, there is accelerated tumor growth with an increase in tumor weight and a decline in their histopathological grades. In addition, tumors from cathepsin B-overexpressing mice exhibit increased numbers of tumor-associated B cells, mast cells and endothelial cells (Vasiljeva et al. 2006; Sevenich et al. 2011).

Splice Variants

Author Manuscript

Although the mechanisms for regulating cathepsin B mRNA splicing remain unclear, cathepsin B variants can be subdivided into two subpopulations that give rise to two distinct translation products (Gong et al. 1993; Berquin et al. 1995; Mehtani et al. 1998; Berardi et al. 2001). The first group of variants lacks exon 2 [CB(−2)] and was originally observed in malignant tumors overexpressing cathepsin B (Gong et al. 1993). Although CB(−2) encodes the same enzyme as the full-length CB transcript and its distribution is unaltered, its translation rate is doubled (Gong et al. 1993). This altered rate of translation and hence increased expression may augment pathologies including tumorigenesis (Gong et al. 1993) and osteoarthritis (Berardi et al. 2001). The second group lacks exons 2 and 3 [CB(−2,3)], thus translation starts at an initiation codon at position 53 within exon 4. This mRNA variant is translated into a naturally truncated form of cathepsin B (Δ51CB) that is not distributed to intracellular vesicles, i.e., endosomal/lysosomal compartments, and has no cathepsin B enzymatic activity (Müntener et al. 2004; Müntener et al. 2005). Δ51CB is more prominently expressed in tumors (Mehtani et al. 1998) and arthritic tissues/cells (Berardi et al. 2001). Δ51CB is also found to be associated with the nucleus, the cytoplasmic side of intracellular membranes (Mehtani et al. 1998) and mitochondria (Müntener et al. 2004). Furthermore, its overexpression stimulates nuclear fragmentation and cell death (Müntener et al. 2003; Bestvater et al. 2005).

Author Manuscript

Antibodies Several monoclonal and polyclonal antibodies to both human and murine cathepsin B are available both commercially and from individual laboratories. Polyclonal antibodies are available that recognize all forms of the enzyme. Monoclonal antibodies have been developed that recognize specific epitopes in the mature enzyme, as well as others that recognize only epitopes within the propeptide. These antibodies detect cathepsin B in immunoblots and in both cultured cells and histological tissue sections. In addition, a

AFCS Nat Mol Pages. Author manuscript; available in PMC 2017 August 03.

Cavallo-Medved et al.

Page 11

Author Manuscript

monoclonal antibody 2A2 has been developed that regulates cathepsin B activity by inducing a change in conformation of the enzyme. This change results in stabilization of the exopeptidase conformation and neutralization of the endopeptidase activity (Mirković et al. 2009).

References

Author Manuscript Author Manuscript Author Manuscript

Abdollahi A, Getts LA, Sonoda G, Miller PD, Taguchi T, Godwin AK, Testa JR, Hamilton TC. Genome scanning detects amplification of the cathepsin B gene (CtsB) in transformed rat ovarian surface epithelial cells. J Soc Gynecol Investig. 1999 Jan-Feb;6:1. Abrahamson M, Alvarez-Fernandez M, Nathanson CM. Cystatins. Biochem Soc Symp. 2003 Almeida PC, Nantes IL, Chagas JR, Rizzi CC, Faljoni-Alario A, Carmona E, Juliano L, Nader HB, Tersariol IL. Cathepsin B activity regulation. Heparin-like glycosaminogylcans protect human cathepsin B from alkaline pH-induced inactivation. J Biol Chem. 2001; 276:2. Arkona C, Wiederanders B. Expression, subcellular distribution and plasma membrane binding of cathepsin B and gelatinases in bone metastatic tissue. Biol Chem. 1996; 377:11. Baici A, Müntener K, Willimann A, Zwicky R. Regulation of human cathepsin B by alternative mRNA splicing: homeostasis, fatal errors and cell death. Biol Chem. 2006; 387:8. Balaji KN, Schaschke N, Machleidt W, Catalfamo M, Henkart PA. Surface cathepsin B protects cytotoxic lymphocytes from self-destruction after degranulation. J Exp Med. 2002; 196:4. Barrett AJ, Fritz H, Grubb A, Isemura S, Järvinen M, Katunuma N, Machleidt W, Müller-Esterl W, Sasaki M, Turk V. Nomenclature and classification of the proteins homologous with the cysteineproteinase inhibitor chicken cystatin. Biochem J. 1986; 236:1. [PubMed: 3539097] Berardi S, Lang A, Kostoulas G, Hörler D, Vilei EM, Baici A. Alternative messenger RNA splicing and enzyme forms of cathepsin B in human osteoarthritic cartilage and cultured chondrocytes. Arthritis Rheum. 2001; 44:8. Berquin IM, Cao L, Fong D, Sloane BF. Identification of two new exons and multiple transcription start points in the 5′-untranslated region of the human cathepsin-B-encoding gene. Gene. 1995; 159:2. Berquin IM, Yan S, Katiyar K, Huang L, Sloane BF, Troen BR. Differentiating agents regulate cathepsin B gene expression in HL-60 cells. J Leukoc Biol. 1999; 66:4. Bestvater F, Dallner C, Spiess E. The C-terminal subunit of artificially truncated human cathepsin B mediates its nuclear targeting and contributes to cell viability. BMC Cell Biol. 2005; 6:1. [PubMed: 15649318] Bojic L, Petelin A, Stoka V, Reinheckel T, Peters C, Turk V, Turk B. Cysteine cathepsins are not involved in Fas/CD95 signalling in primary skin fibroblasts. FEBS Lett. 2007; 581:27. Brix K, Lemansky P, Herzog V. Evidence for extracellularly acting cathepsins mediating thyroid hormone liberation in thyroid epithelial cells. Endocrinology. 1996; 137:5. Brzin J, Rogelj B, Popovic T, Strukelj B, Ritonja A. Clitocypin, a new type of cysteine proteinase inhibitor from fruit bodies of mushroom clitocybe nebularis. J Biol Chem. 2000; 275:26. Buck MR, Karustis DG, Day NA, Honn KV, Sloane BF. Degradation of extracellular-matrix proteins by human cathepsin B from normal and tumour tissues. Biochem J. Feb 15.1992 282(Pt 1) Caglic D, Pungercar JR, Pejler G, Turk V, Turk B. Glycosaminoglycans facilitate procathepsin B activation through disruption of propeptide-mature enzyme interactions. J Biol Chem. 2007; 282:45. Campo E, Muñoz J, Miquel R, Palacín A, Cardesa A, Sloane BF, Emmert-Buck MR. Cathepsin B expression in colorectal carcinomas correlates with tumor progression and shortened patient survival. Am J Pathol. 1994; 145:2. Castiglioni T, Merino MJ, Elsner B, Lah TT, Sloane BF, Emmert-Buck MR. Immunohistochemical analysis of cathepsins D, B, and L in human breast cancer. Hum Pathol. 1994; 25:9. Cavallo-Medved D, Dosescu J, Linebaugh BE, Sameni M, Rudy D, Sloane BF. Mutant K-ras regulates cathepsin B localization on the surface of human colorectal carcinoma cells. Neoplasia. 2003 NovDec;5:6. AFCS Nat Mol Pages. Author manuscript; available in PMC 2017 August 03.

Cavallo-Medved et al.

Page 12

Author Manuscript Author Manuscript Author Manuscript Author Manuscript

Cavallo-Medved D, Mai J, Dosescu J, Sameni M, Sloane BF. Caveolin-1 mediates the expression and localization of cathepsin B, prourokinase plasminogen activator and their cell-surface receptors in human colorectal carcinoma cells. J Cell Sci. Apr 1.2005 118(Pt 7) Cavallo-Medved D, Rudy D, Blum G, Bogyo M, Caglic D, Sloane BF. Live-cell imaging demonstrates extracellular matrix degradation in association with active cathepsin B in caveolae of endothelial cells during tube formation. Exp Cell Res. 2009; 315:7. Cavallo-Medved D, Sloane BF. Cell-surface cathepsin B: understanding its functional significance. Curr Top Dev Biol. 54:2003. Cavanaugh PG, Sloane BF, Bajkowski AS, Gasic GJ, Gasic TB, Honn KV. Involvement of a cathepsin B-like cysteine proteinase in platelet aggregation induced by tumor cells and their shed membrane vesicles. Clin Exp Metastasis. 1983 Oct-Dec;1:4. Cezari MH, Puzer L, Juliano MA, Carmona AK, Juliano L. Cathepsin B carboxydipeptidase specificity analysis using internally quenched fluorescent peptides. Biochem J. Nov 15.2002 368(Pt 1) Chen J, Tung CH, Mahmood U, Ntziachristos V, Gyurko R, Fishman MC, Huang PL, Weissleder R. In vivo imaging of proteolytic activity in atherosclerosis. Circulation. 2002; 105:23. Choe Y, Leonetti F, Greenbaum DC, Lecaille F, Bogyo M, Brömme D, Ellman JA, Craik CS. Substrate profiling of cysteine proteases using a combinatorial peptide library identifies functionally unique specificities. J Biol Chem. 2006; 281:18. Cirman T, Oresić K, Mazovec GD, Turk V, Reed JC, Myers RM, Salvesen GS, Turk B. Selective disruption of lysosomes in HeLa cells triggers apoptosis mediated by cleavage of Bid by multiple papain-like lysosomal cathepsins. J Biol Chem. 2004; 279:5. Cotrin SS, Puzer L, de Souza Judice WA, Juliano L, Carmona AK, Juliano MA. Positional-scanning combinatorial libraries of fluorescence resonance energy transfer peptides to define substrate specificity of carboxydipeptidases: assays with human cathepsin B. Anal Biochem. 2004; 335:2. Czyzewska J, Guzińska-Ustymowicz K, Kemona A, Bandurski R. The expression of matrix metalloproteinase 9 and cathepsin B in gastric carcinoma is associated with lymph node metastasis, but not with postoperative survival. Folia Histochem Cytobiol. 2008; 46:1. [PubMed: 19103586] Dalet-Fumeron V, Boudjennah L, Pagano M. Competition between plasminogen and procathepsin B as a probe to demonstrate the in vitro activation of procathepsin B by the tissue plasminogen activator. Arch Biochem Biophys. 1996; 335:2. Dalet-Fumeron V, Guinec N, Pagano M. In vitro activation of pro-cathepsin B by three serine proteinases: leucocyte elastase, cathepsin G, and the urokinase-type plasminogen activator. FEBS Lett. 1993; 332:3. Deussing J, Roth W, Saftig P, Peters C, Ploegh HL, Villadangos JA. Cathepsins B and D are dispensable for major histocompatibility complex class II-mediated antigen presentation. Proc Natl Acad Sci U S A. 1998; 95:8. [PubMed: 9419316] Droga-Mazovec G, Bojic L, Petelin A, Ivanova S, Romih R, Repnik U, Salvesen GS, Stoka V, Turk V, Turk B. Cysteine cathepsins trigger caspase-dependent cell death through cleavage of bid and antiapoptotic Bcl-2 homologues. J Biol Chem. 2008; 283:27. Felbor U, Kessler B, Mothes W, Goebel HH, Ploegh HL, Bronson RT, Olsen BR. Neuronal loss and brain atrophy in mice lacking cathepsins B and L. Proc Natl Acad Sci U S A. 2002; 99:12. Fernández PL, Farré X, Nadal A, Fernández E, Peiró N, Sloane BF, Shi GP, Chapman HA, Campo E, Cardesa A. Expression of cathepsins B and S in the progression of prostate carcinoma. Int J Cancer. 2001; 95:1. [PubMed: 11241302] Foekens JA, Kos J, Peters HA, Krasovec M, Look MP, Cimerman N, Meijervan Gelder ME, HenzenLogmans SC, van Putten WL, Klijn JG. Prognostic significance of cathepsins B and L in primary human breast cancer. J Clin Oncol. 1998; 16:3. [PubMed: 9440715] Fong D, Chan MM, Hsieh WT, Menninger JC, Ward DC. Confirmation of the human cathepsin B gene (CTSB) assignment to chromosome 8. Hum Genet. 1992; 89:1. [PubMed: 1577455] Gocheva V, Zeng W, Ke D, Klimstra D, Reinheckel T, Peters C, Hanahan D, Joyce JA. Distinct roles for cysteine cathepsin genes in multistage tumorigenesis. Genes Dev. 2006; 20:5.

AFCS Nat Mol Pages. Author manuscript; available in PMC 2017 August 03.

Cavallo-Medved et al.

Page 13

Author Manuscript Author Manuscript Author Manuscript Author Manuscript

Gong Q, Chan SJ, Bajkowski AS, Steiner DF, Frankfater A. Characterization of the cathepsin B gene and multiple mRNAs in human tissues: evidence for alternative splicing of cathepsin B premRNA. DNA Cell Biol. 1993; 12:4. Gosalia DN, Salisbury CM, Ellman JA, Diamond SL. High throughput substrate specificity profiling of serine and cysteine proteases using solution-phase fluorogenic peptide microarrays. Mol Cell Proteomics. 2005; 4:5. Guicciardi ME, Bronk SF, Werneburg NW, Gores GJ. cFLIPL prevents TRAIL-induced apoptosis of hepatocellular carcinoma cells by inhibiting the lysosomal pathway of apoptosis. Am J Physiol Gastrointest Liver Physiol. 2007; 292:5. Guicciardi ME, Deussing J, Miyoshi H, Bronk SF, Svingen PA, Peters C, Kaufmann SH, Gores GJ. Cathepsin B contributes to TNF-alpha-mediated hepatocyte apoptosis by promoting mitochondrial release of cytochrome c. J Clin Invest. 2000; 106:9. [PubMed: 10880042] Guicciardi ME, Miyoshi H, Bronk SF, Gores GJ. Cathepsin B knockout mice are resistant to tumor necrosis factor-alpha-mediated hepatocyte apoptosis and liver injury: implications for therapeutic applications. Am J Pathol. 2001; 159:6. Guo M, Mathieu PA, Linebaugh B, Sloane BF, Reiners JJ. Phorbol ester activation of a proteolytic cascade capable of activating latent transforming growth factor-betaL a process initiated by the exocytosis of cathepsin B. J Biol Chem. 2002; 277:17. Hajjar KA, Jacovina AT, Chacko J. An endothelial cell receptor for plasminogen/tissue plasminogen activator. I. Identity with annexin II. J Biol Chem. 1994; 269:33. [PubMed: 8276815] Halangk W, Lerch MM, Brandt-Nedelev B, Roth W, Ruthenbuerger M, Reinheckel T, Domschke W, Lippert H, Peters C, Deussing J. Role of cathepsin B in intracellular trypsinogen activation and the onset of acute pancreatitis. J Clin Invest. 2000; 106:6. Hansen T, Petrow PK, Gaumann A, Keyszer GM, Eysel P, Eckardt A, Bräuer R, Kriegsmann J. Cathepsin B and its endogenous inhibitor cystatin C in rheumatoid arthritis synovium. J Rheumatol. 2000; 27:4. [PubMed: 10648009] Hashimoto Y, Kakegawa H, Narita Y, Hachiya Y, Hayakawa T, Kos J, Turk V, Katunuma N. Significance of cathepsin B accumulation in synovial fluid of rheumatoid arthritis. Biochem Biophys Res Commun. 2001; 283:2. Hasnain S, Hirama T, Huber CP, Mason P, Mort JS. Characterization of cathepsin B specificity by sitedirected mutagenesis. Importance of Glu245 in the S2-P2 specificity for arginine and its role in transition state stabilization. J Biol Chem. 1993; 268:1. [PubMed: 8416916] Honn KV, Timár J, Rozhin J, Bazaz R, Sameni M, Ziegler G, Sloane BF. A lipoxygenase metabolite, 12-(S)-HETE, stimulates protein kinase C-mediated release of cathepsin B from malignant cells. Exp Cell Res. 1994; 214:1. [PubMed: 8082713] Hook V, Toneff T, Bogyo M, Greenbaum D, Medzihradszky KF, Neveu J, Lane W, Hook G, Reisine T. Inhibition of cathepsin B reduces beta-amyloid production in regulated secretory vesicles of neuronal chromaffin cells: evidence for cathepsin B as a candidate beta-secretase of Alzheimer’s disease. Biol Chem. 2005; 386:9. Hook VY, Kindy M, Hook G. Inhibitors of cathepsin B improve memory and reduce beta-amyloid in transgenic Alzheimer disease mice expressing the wild-type, but not the Swedish mutant, betasecretase site of the amyloid precursor protein. J Biol Chem. 2008; 283:12. Hook VY, Kindy M, Reinheckel T, Peters C, Hook G. Genetic cathepsin B deficiency reduces betaamyloid in transgenic mice expressing human wild-type amyloid precursor protein. Biochem Biophys Res Commun. 2009; 386:2. Hughes SJ, Glover TW, Zhu XX, Kuick R, Thoraval D, Orringer MB, Beer DG, Hanash S. A novel amplicon at 8p22-23 results in overexpression of cathepsin B in esophageal adenocarcinoma. Proc Natl Acad Sci U S A. 1998; 95:21. Illy C, Quraishi O, Wang J, Purisima E, Vernet T, Mort JS. Role of the occluding loop in cathepsin B activity. J Biol Chem. 1997; 272:2. Jane DT, DaSilva L, Koblinski J, Horwitz M, Sloane BF, Dufresne MJ. Evidence for the involvement of cathepsin B in skeletal myoblast differentiation. J Cell Biochem. 2002; 84:3.

AFCS Nat Mol Pages. Author manuscript; available in PMC 2017 August 03.

Cavallo-Medved et al.

Page 14

Author Manuscript Author Manuscript Author Manuscript Author Manuscript

Jane DT, Morvay LC, Koblinski J, Yan S, Saad FA, Sloane BF, Dufresne MJ. Evidence that E-box promoter elements and MyoD transcription factors play a role in the induction of cathepsin B gene expression during human myoblast differentiation. Biol Chem. 2002; 383:12. Jedeszko C, Sloane BF. Cysteine cathepsins in human cancer. Biol Chem. 2004; 385:11. [PubMed: 14977041] Joyce JA, Baruch A, Chehade K, Meyer-Morse N, Giraudo E, Tsai FY, Greenbaum DC, Hager JH, Bogyo M, Hanahan D. Cathepsin cysteine proteases are effectors of invasive growth and angiogenesis during multistage tumorigenesis. Cancer Cell. 2004; 5:5. [PubMed: 14749120] Kassam G, Choi KS, Ghuman J, Kang HM, Fitzpatrick SL, Zackson T, Zackson S, Toba M, Shinomiya A, Waisman DM. The role of annexin II tetramer in the activation of plasminogen. J Biol Chem. 1998; 273:8. Kassam G, Manro A, Braat CE, Louie P, Fitzpatrick SL, Waisman DM. Characterization of the heparin binding properties of annexin II tetramer. J Biol Chem. 1997; 272:24. [PubMed: 8995219] Kim DE, Kim JY, Schellingerhout D, Shon SM, Jeong SW, Kim EJ, Kim WK. Molecular imaging of cathepsin B proteolytic enzyme activity reflects the inflammatory component of atherosclerotic pathology and can quantitatively demonstrate the antiatherosclerotic therapeutic effects of atorvastatin and glucosamine. Mol Imaging. 2009 Sep-Oct;8:5. Kirschke H, Barrett AJ, Rawlings ND. Proteinases 1: lysosomal cysteine proteinases. Protein Profile. 1995; 2:14. Kobayashi H, Schmitt M, Goretzki L, Chucholowski N, Calvete J, Kramer M, Günzler WA, Jänicke F, Graeff H. Cathepsin B efficiently activates the soluble and the tumor cell receptor-bound form of the proenzyme urokinase-type plasminogen activator (Pro-uPA). J Biol Chem. 1991; 266:8. Kuliawat R, Arvan P. Distinct molecular mechanisms for protein sorting within immature secretory granules of pancreatic beta-cells. J Cell Biol. 1994; 126:1. [PubMed: 8027170] Lemaire R, Huet G, Zerimech F, Grard G, Fontaine C, Duquesnoy B, Flipo RM. Selective induction of the secretion of cathepsins B and L by cytokines in synovial fibroblast-like cells. Br J Rheumatol. 1997; 36:7. Lenarcic B, Krishnan G, Borukhovich R, Ruck B, Turk V, Moczydlowski E. Saxiphilin, a saxitoxinbinding protein with two thyroglobulin type 1 domains, is an inhibitor of papain-like cysteine proteinases. J Biol Chem. 2000; 275:20. Lenarcic B, Ritonja A, Strukelj B, Turk B, Turk V. Equistatin, a new inhibitor of cysteine proteinases from Actinia equina, is structurally related to thyroglobulin type-1 domain. J Biol Chem. 1997; 272:21. Lerch MM, Halangk W. Human pancreatitis and the role of cathepsin B. Gut. 2006; 55:9. Linebaugh BE, Sameni M, Day NA, Sloane BF, Keppler D. Exocytosis of active cathepsin B enzyme activity at pH 7.0, inhibition and molecular mass. Eur J Biochem. 1999; 264:1. [PubMed: 10447667] Linke M, Jordans S, Mach L, Herzog V, Brix K. Thyroid stimulating hormone upregulates secretion of cathepsin B from thyroid epithelial cells. Biol Chem. 2002; 383:5. [PubMed: 11928822] Liu J, Guo Q, Chen B, Yu Y, Lu H, Li YY. Cathepsin B and its interacting proteins, bikunin and TSRC1, correlate with TNF-induced apoptosis of ovarian cancer cells OV-90. FEBS Lett. 2006; 580:1. Liu JP, Liu NS, Yuan HY, Guo Q, Lu H, Li YY. Human homologue of SETA binding protein 1 interacts with cathepsin B and participates in TNF-Induced apoptosis in ovarian cancer cells. Mol Cell Biochem. 2006; 292:1–2. [PubMed: 16983501] Liu N, Raja SM, Zazzeroni F, Metkar SS, Shah R, Zhang M, Wang Y, Brömme D, Russin WA, Lee JC, Peter ME, Froelich CJ, Franzoso G, Ashton-Rickardt PG. NF-kappaB protects from the lysosomal pathway of cell death. EMBO J. 2003; 22:19. Li W, Dalen H, Eaton JW, Yuan XM. Apoptotic death of inflammatory cells in human atheroma. Arterioscler Thromb Vasc Biol. 2001; 21:7. Li W, Yuan XM. Increased expression and translocation of lysosomal cathepsins contribute to macrophage apoptosis in atherogenesis. Ann N Y Acad Sci. Dec.2004 1030 Li Z, Berk M, McIntyre TM, Gores GJ, Feldstein AE. The lysosomal-mitochondrial axis in free fatty acid-induced hepatic lipotoxicity. Hepatology. 2008; 47:5. [PubMed: 18161717] AFCS Nat Mol Pages. Author manuscript; available in PMC 2017 August 03.

Cavallo-Medved et al.

Page 15

Author Manuscript Author Manuscript Author Manuscript Author Manuscript

Lutgens SP, Cleutjens KB, Daemen MJ, Heeneman S. Cathepsin cysteine proteases in cardiovascular disease. FASEB J. 2007; 21:12. Maciewicz RA, Wotton SF, Etherington DJ, Duance VC. Susceptibility of the cartilage collagens types II, IX and XI to degradation by the cysteine proteinases, cathepsins B and L. FEBS Lett. 1990; 269:1. [PubMed: 2143734] Mai J, Finley RL, Waisman DM, Sloane BF. Human procathepsin B interacts with the annexin II tetramer on the surface of tumor cells. J Biol Chem. 2000; 275:17. Mehtani S, Gong Q, Panella J, Subbiah S, Peffley DM, Frankfater A. In vivo expression of an alternatively spliced human tumor message that encodes a truncated form of cathepsin B. Subcellular distribution of the truncated enzyme in COS cells. J Biol Chem. 1998; 273:21. Mirković B, Premzl A, Hodnik V, Doljak B, Jevnikar Z, Anderluh G, Kos J. Regulation of cathepsin B activity by 2A2 monoclonal antibody. FEBS J. 2009; 276:17. Mohamed MM, Sloane BF. Cysteine cathepsins: multifunctional enzymes in cancer. Nat Rev Cancer. 2006; 6:10. Moin K, Cao L, Day NA, Koblinski JE, Sloane BF. Tumor cell membrane cathepsin B. Biol Chem. 1998 Aug-Sep;379:8–9. Mort JS, Buttle DJ. Cathepsin B. Int J Biochem Cell Biol. 1997; 29:5. [PubMed: 9076937] Müntener K, Willimann A, Zwicky R, Svoboda B, Mach L, Baici A. Folding competence of Nterminally truncated forms of human procathepsin B. J Biol Chem. 2005; 280:12. Müntener K, Zwicky R, Csucs G, Baici A. The alternative use of exons 2 and 3 in cathepsin B mRNA controls enzyme trafficking and triggers nuclear fragmentation in human cells. Histochem Cell Biol. 2003; 119:2. Müntener K, Zwicky R, Csucs G, Rohrer J, Baici A. Exon skipping of cathepsin B: mitochondrial targeting of a lysosomal peptidase provokes cell death. J Biol Chem. 2004; 279:39. Musil D, Zucic D, Turk D, Engh RA, Mayr I, Huber R, Popovic T, Turk V, Towatari T, Katunuma N, et al. The refined 2.15 A X-ray crystal structure of human liver cathepsin B: the structural basis for its specificity. EMBO J. 1991; 10:9. Nägler DK, Storer AC, Portaro FC, Carmona E, Juliano L, Ménard R. Major increase in endopeptidase activity of human cathepsin B upon removal of occluding loop contacts. Biochemistry. 1997; 36:41. [PubMed: 8993316] Nycander M, Estrada S, Mort JS, Abrahamson M, Björk I. Two-step mechanism of inhibition of cathepsin B by cystatin C due to displacement of the proteinase occluding loop. FEBS Lett. 1998; 422:1. [PubMed: 9475157] Pavlova A, Krupa JC, Mort JS, Abrahamson M, Björk I. Cystatin inhibition of cathepsin B requires dislocation of the proteinase occluding loop. Demonstration By release of loop anchoring through mutation of his110. FEBS Lett. 2000; 487:2. Podobnik M, Kuhelj R, Turk V, Turk D. Crystal structure of the wild-type human procathepsin B at 2.5 A resolution reveals the native active site of a papain-like cysteine protease zymogen. J Mol Biol. 1997; 271:5. Pungercar JR, Caglic D, Sajid M, Dolinar M, Vasiljeva O, Pozgan U, Turk D, Bogyo M, Turk V, Turk B. Autocatalytic processing of procathepsin B is triggered by proenzyme activity. FEBS J. 2009; 276:3. Reiser J, Adair B, Reinheckel T. Specialized roles for cysteine cathepsins in health and disease. J Clin Invest. 2010; 120:10. Rempel SA, Rosenblum ML, Mikkelsen T, Yan PS, Ellis KD, Golembieski WA, Sameni M, Rozhin J, Ziegler G, Sloane BF. Cathepsin B expression and localization in glioma progression and invasion. Cancer Res. 1994; 54:23. Renko M, Požgan U, Majera D, Turk D. Stefin A displaces the occluding loop of cathepsin B only by as much as required to bind to the active site cleft. FEBS J. 2010; 277:20. Roshy S, Sloane BF, Moin K. Pericellular cathepsin B and malignant progression. Cancer Metastasis Rev. 2003 Jun-Sep;22:2–3. Rozhin J, Sameni M, Ziegler G, Sloane BF. Pericellular pH affects distribution and secretion of cathepsin B in malignant cells. Cancer Res. 1994; 54:24.

AFCS Nat Mol Pages. Author manuscript; available in PMC 2017 August 03.

Cavallo-Medved et al.

Page 16

Author Manuscript Author Manuscript Author Manuscript Author Manuscript

Rozman J, Stojan J, Kuhelj R, Turk V, Turk B. Autocatalytic processing of recombinant human procathepsin B is a bimolecular process. FEBS Lett. 1999; 459:3. Sameni M, Elliott E, Ziegler G, Fortgens PH, Dennison C, Sloane BF. Cathepsin B and D are Localized at the Surface of Human Breast Cancer Cells. Pathol Oncol Res. 1995; 1:1. Sameni M, Moin K, Sloane BF. Imaging proteolysis by living human breast cancer cells. Neoplasia. 2000 Nov-Dec;2:6. Scorilas A, Fotiou S, Tsiambas E, Yotis J, Kotsiandri F, Sameni M, Sloane BF, Talieri M. Determination of cathepsin B expression may offer additional prognostic information for ovarian cancer patients. Biol Chem. 2002 Jul-Aug;383:7–8. Sevenich L, Pennacchio LA, Peters C, Reinheckel T. Human cathepsin L rescues the neurodegeneration and lethality in cathepsin B/L double-deficient mice. Biol Chem. 2006; 387:7. Sevenich L, Werner F, Gajda M, Schurigt U, Sieber C, Müller S, Follo M, Peters C, Reinheckel T. Transgenic expression of human cathepsin B promotes progression and metastasis of polyomamiddle-T- induced breast cancer in mice. Oncogene. 2011; 30:1. [PubMed: 20935674] Sinha AA, Quast BJ, Wilson MJ, Fernandes ET, Reddy PK, Ewing SL, Gleason DF. Prediction of pelvic lymph node metastasis by the ratio of cathepsin B to stefin A in patients with prostate carcinoma. Cancer. 2002; 94:12. Sloane BF, Moin K, Sameni M, Tait LR, Rozhin J, Ziegler G. Membrane association of cathepsin B can be induced by transfection of human breast epithelial cells with c- Ha-ras oncogene. J Cell Sci. Feb.1994 107(Pt 2) Sloane BF, Rozhin J, Johnson K, Taylor H, Crissman JD, Honn KV. Cathepsin B: association with plasma membrane in metastatic tumors. Proc Natl Acad Sci U S A. 1986; 83:8. Szpaderska AM, Silberman S, Ahmed Y, Frankfater A. Sp1 regulates cathepsin B transcription and invasiveness in murine B16 melanoma cells. Anticancer Res. 2004 Nov-Dec;24:6. Takahashi T, Schmidt PG, Tang J. Novel carbohydrate structures of cathepsin B from porcine spleen. J Biol Chem. 1984; 259:10. Tam SW, Cote-Paulino LR, Peak DA, Sheahan K, Murnane MJ. Human cathepsin B-encoding cDNAs: sequence variations in the 3′-untranslated region. Gene. 1994; 139:2. Tedelind S, Poliakova K, Valeta A, Hunegnaw R, Yemanaberhan EL, Heldin NE, Kurebayashi J, Weber E, Kopitar-Jerala N, Turk B, Bogyo M, Brix K. Nuclear cysteine cathepsin variants in thyroid carcinoma cells. Biol Chem. 2010; 391:8. Tertov VV, Orekhov AN. Metabolism of native and naturally occurring multiple modified low density lipoprotein in smooth muscle cells of human aortic intima. Exp Mol Pathol. 1997; 64:3. Tu C, Ortega-Cava CF, Chen G, Fernandes ND, Cavallo-Medved D, Sloane BF, Band V, Band H. Lysosomal cathepsin B participates in the podosome-mediated extracellular matrix degradation and invasion via secreted lysosomes in v-Src fibroblasts. Cancer Res. 2008; 68:22. [PubMed: 18172292] Turk B, Turk V, Turk D. Structural and functional aspects of papain-like cysteine proteinases and their protein inhibitors. Biol Chem. 1997 Mar-Apr;378:3–4. Turk D, Podobnik M, Kuhelj R, Dolinar M, Turk V. Crystal structures of human procathepsin B at 3.2 and 3.3 Angstroms resolution reveal an interaction motif between a papain-like cysteine protease and its propeptide. FEBS Lett. 1996; 384:3. Turk V, Bode W. The cystatins: protein inhibitors of cysteine proteinases. FEBS Lett. 1991; 285:2. van Acker GJ, Perides G, Steer ML. Co-localization hypothesis: a mechanism for the intrapancreatic activation of digestive enzymes during the early phases of acute pancreatitis. World J Gastroenterol. 2006; 12:13. Van Acker GJ, Saluja AK, Bhagat L, Singh VP, Song AM, Steer ML. Cathepsin B inhibition prevents trypsinogen activation and reduces pancreatitis severity. Am J Physiol Gastrointest Liver Physiol. 2002; 283:3. van der Stappen JW, Williams AC, Maciewicz RA, Paraskeva C. Activation of cathepsin B, secreted by a colorectal cancer cell line requires low pH and is mediated by cathepsin D. Int J Cancer. 1996; 67:4.

AFCS Nat Mol Pages. Author manuscript; available in PMC 2017 August 03.

Cavallo-Medved et al.

Page 17

Author Manuscript Author Manuscript

Vasiljeva O, Korovin M, Gajda M, Brodoefel H, Bojic L, Krüger A, Schurigt U, Sevenich L, Turk B, Peters C, Reinheckel T. Reduced tumour cell proliferation and delayed development of highgrade mammary carcinomas in cathepsin B-deficient mice. Oncogene. 2008; 27:30. Vasiljeva O, Papazoglou A, Krüger A, Brodoefel H, Korovin M, Deussing J, Augustin N, Nielsen BS, Almholt K, Bogyo M, Peters C, Reinheckel T. Tumor cell-derived and macrophage- derived cathepsin B promotes progression and lung metastasis of mammary cancer. Cancer Res. 2006; 66:10. [PubMed: 16397207] Wasylyk C, Wasylyk B. Oncogenic conversion alters the transcriptional properties of ets. Cell Growth Differ. 1992; 3:9. Yamashita M, Konagaya S. A novel cysteine protease inhibitor of the egg of chum salmon, containing a cysteine-rich thyroglobulin-like motif. J Biol Chem. 1996; 271:3. Yan S, Berquin IM, Troen BR, Sloane BF. Transcription of human cathepsin B is mediated by Sp1 and Ets family factors in glioma. DNA Cell Biol. 2000; 19:2. Yan S, Jane DT, Dufresne MJ, Sloane BF. Transcription of cathepsin B in glioma cells: regulation by an E-box adjacent to the transcription initiation site. Biol Chem. 2003 Oct-Nov;384:10–11. Yan S, Sloane BF. Isolation of a novel USF2 isoform: repressor of cathepsin B expression. Gene. Aug 4.2004 337 Yan S, Sloane BF. Molecular regulation of human cathepsin B: implication in pathologies. Biol Chem. 2003; 384:6. Yan Z, Deng X, Chen M, Xu Y, Ahram M, Sloane BF, Friedman E. Oncogenic c-Ki-ras but not oncogenic c-Ha-ras up-regulates CEA expression and disrupts basolateral polarity in colon epithelial cells. J Biol Chem. 1997; 272:44. [PubMed: 8995224] Zwicky R, Müntener K, Csucs G, Goldring MB, Baici A. Exploring the role of 5′ alternative splicing and of the 3′-untranslated region of cathepsin B mRNA. Biol Chem. 2003; 384:7.

Author Manuscript Author Manuscript AFCS Nat Mol Pages. Author manuscript; available in PMC 2017 August 03.

Cathepsin B: Basis Sequence: Mouse.

Cathepsin B: Basis Sequence: Mouse. - PDF Download Free
NAN Sizes 1 Downloads 12 Views